Patient with metastatic colorectal cancer treated in the third line of therapy with trifluridin/tipiracil

04/2018

MUDr. Jan Prokš, doc. MUDr. Josef Dvořák, Ph.D.

Onkologická klinika 1. LF UK a Thomayerovy nemocnice, Praha

SUMMARY

2015 was approved, after the placebo controled phase III trial RECOURSE, trifluridin/tipiracil (Lonsurf®, formerly TAS 102) for the treatment of patients with metastatic colorectal cancer who have been treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. Trifluridin/tipiracil is an oral analog of fluoropyrimidin in combination with thymidinfosforylase inhibitor. Following case report demonstrates efficiency and good tolerance in the third line of therapy of the patient with metastatic colorectal cancer.

KEY WORDS

colorectal cancer, trifluridin/tipiracil, third line of therapy